While GLP-1 receptor agonists and tirzepatide do not cause hypoglycemia when used as monotherapy, there is a risk of additive hypoglycemia when combined with sulfonylureas or insulin, with close monitoring and downward dose adjustment or withdrawal of background hypoglycemic agents (e.g., sulfonylureas, insulin) recommended to avoid unnecessary hypoglycemic events [23]. This evidence concerns the gene INS and Hypoglycemia.